Researchers from the VIB-KU Leuven Center for Microbiology in Belgium have developed a novel screening method for identifying antimicrobial properties in certain plant-derived volatile substances.

The researchers aimed to address the growing antifungal drug resistance challenges by using new experimental techniques and repurposing existing compounds.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Using the screening method, researchers identified volatile substances that were active against the most drug-resistant type of Candida, the most common cause of fungal infections worldwide.

They believed that plant essential oils (EOs), metabolites extracted by steam distillation or cold citrus peel pressing, could be used to treat fungal infections as they contain compounds that protect the plant from microbial or herbivore attacks.

The researchers developed the new screening method in order to identify biologically active compounds with antifungal properties in mixtures of 37 EO components and 175 EOs, comprised of more than 1,000 different small molecules.

“Think of possibilities such as maintaining hygiene in hospitals or treating patients with lung infections.”

Upon testing their vapour-phase-mediated activity, it was observed that around half of the substances were active against both Candida albicans and Candida glabrata.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

VIB-KU Leuven Center for Microbiology professor Patrick Van Dijck said: “We screened our whole collection of EOs for vapour-phase mediated antifungal activity against two human fungal pathogens, Candida albicans and Candida glabrata.

“Surprisingly, C. glabrata, the most drug-resistant species of the two was on average even more susceptible. In contrast, none of the currently used antifungals showed any vapour-phase-mediated activity.”

The researchers predict that as well as antimicrobial properties, the new assay could also be used to assess other biological activities.

Co-researcher Adam Feyaerts said: “Our findings are for instance a starting point for the development of molecules that could also be used in vaporisers. After all, volatiles can access otherwise hard to reach areas.

“Think of possibilities such as maintaining hygiene in hospitals or treating patients with lung infections.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact